Trimetazidine ( DrugBank: Trimetazidine )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	2
58	Hypertrophic cardiomyopathy	2
86	Pulmonary arterial hypertension	1

2. Amyotrophic lateral sclerosis

---

Clinical trials : 624 /  Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04788745 (ClinicalTrials.gov)	June 29, 2021	2/3/2021	Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)	Targeting Metabolic Flexibility in ALS (MetFlex); Safety and Tolerability of Trimetazidine for the Treatment of ALS	Amyotrophic Lateral Sclerosis;Motor Neuron Disease	Drug: Trimetazidine Dihydrochloride	The University of Queensland	FightMND;UMC Utrecht;King's College London;Julius Clinical, The Netherlands	Recruiting	18 Years	75 Years	All	36	Phase 2	Australia;Netherlands;United Kingdom
2	EUCTR2020-005018-17-NL (EUCTR)	14/05/2021	08/04/2021	Safety and tolerability of Trimetazidine in amyotrophic lateral sclerosis (ALS)	Targeting metabolic flexibility in ALS (MetFlex); Safety and tolerability of Trimetazidine for the treatment of ALS - MetFlex	Patients suffering from amyotrophic lateral sclerosis (ALS);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Vastarel Product Name: Trimetazidine Product Code: 201600930	The University of Queensland	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	36	Phase 2	Australia;Netherlands

58. Hypertrophic cardiomyopathy

---

Clinical trials : 119 /  Drugs : 163 - (DrugBank : 45) / Drug target genes : 48 - Drug target pathways : 161

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01696370 (ClinicalTrials.gov)	April 2012	27/9/2012	Trimetazidine Therapy in Hypertrophic Cardiomyopathy	A Phase 2b Randomised, Double Blind, Placebo-controlled Trial of Trimetazidine Therapy in Patients With Non-obstructive Hypertrophic Cardiomyopathy	Hypertrophic Cardiomyopathy	Drug: Trimetazidine;Other: Placebo capsule	University College, London	British Heart Foundation	Recruiting	18 Years	N/A	Both	90	Phase 2	United Kingdom
2	EUCTR2011-000038-12-GB (EUCTR)	13/09/2011	17/08/2011	Trimetazidine therapy in Hypertrophic Cardiomyopathy	A Phase 2b randomised, double blind, placebo-controlled trial of trimetazidine therapy in patients with non-obstructive hypertrophic cardiomyopathy. - Trimetazidine therapy in hypertrophic cardiomyopathy	Hypertrophic cardiomyopathy (non-obstructive) MedDRA version: 16.1;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Vastarel 20mg film coated tablets Product Name: Trimetazidine Dihydrochloride 20mg Product Code: not applicable INN or Proposed INN: trimetazidine dihydrochloride Other descriptive name: 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride	University College London (UCL)	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	United Kingdom

86. Pulmonary arterial hypertension

---

Clinical trials : 1,181 /  Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03273387 (ClinicalTrials.gov)	September 10, 2017	3/9/2017	The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension	The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension Patients in National Cardiovascular Center Harapan Kita Hospital Indonesia	Precapillary Pulmonary Hypertension	Drug: Trimetazidine;Drug: Placebo oral capsule	Indonesia University	NULL	Completed	18 Years	65 Years	All	26	Phase 2/Phase 3	Indonesia

Back to top